partial AUC, early exposure [Regulatives / Guidelines]

posted by d_labes  – Berlin, Germany, 2008-09-03 10:35 (6075 d 23:17 ago) – Posting: # 2308
Views: 24,561

Dear all!

Characteristics to be investigated, page 9 (lines 313-317)
'For products where rapid absorption is of importance, partial AUCs can be used as a measure of early exposure. The partial area can in most cases be truncated at the population median of tmax values for the reference formulation. However, an alternative time point for truncating the partial AUC can be used when clinically relevant. The time point for truncating the partial AUC should be pre-specified and justified in the study protocol.'

This is nearly the same sentence then in the FDA guidance.
It seems partly that this was introduced to get rid of tmax and nonparametric evaluation of that metric.

I wonder how we can interpret "... truncated at population median ...".
What do you think what the population median is?

Helmut has discussed this in the context of data deletion due to emesis in this post.
If I understood his opinion right, the population median is the sample median of the reference formulation (study specific).

But the DRAFT calls for a prespecified truncation point. This I interpret as not study specific but specific for the reference formulation or from clinical relevance (whatever this means).
Where can we get a value for that ominous population median of tmax values for the reference? :ponder:

Next question in that context is: Who decides for which product rapid absorption is important and therefore partial Area should be evaluated?

Regards,

Detlew

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,671 registered users;
24 visitors (0 registered, 24 guests [including 4 identified bots]).
Forum time: 09:52 CEST (Europe/Vienna)

The difference between a surrogate and a true endpoint
is like the difference between a cheque and cash.
You can get the cheque earlier but then,
of course, it might bounce.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5